Table 2 APOA1 rs670 A allele carriage was associated with lymph node and hormone receptor status at baseline
| Â | G/G (n=90) | G/A (n=106) | A/A (n=27) | P valuea |
|---|---|---|---|---|
Age | 46.61±10.14 (29.25-74.55) | 49.98±10.24 (29.87-74.57) | 47.83±9.81 (29.25-67.91) | 0.067 |
BMIb | 23.47±4.14 (15.06-34.48) | 23.03±4.16 (2.25-38.05) | 23.77±3.83 (18.18-32.05) | 0.654 |
Tumor type | ||||
Infiltrating ductal carcinoma | 73 (81.11%) | 97 (91.51%) | 23 (85.19%) | 0.332 |
Ductal carcinoma in situ | 10 (11.11%) | 5 (4.72%) | 2 (7.41%) | |
Others | 5 (5.56%) | 4 (3.77%) | 2 (7.41%) | |
Unknown | 2 (2.22%) | 0 (0.00%) | 0 (0.00%) | |
Side | ||||
Right | 35 (38.89%) | 52 (49.06%) | 13 (48.15%) | 0.704 |
Left | 51 (56.67%) | 50 (47.17%) | 13 (48.15%) | |
Bilateral | 4 (4.44%) | 4 (3.77%) | 1 (3.70%) | |
Tumor size | ||||
<5cm | 64 (71.11%) | 76 (71.70%) | 19 (70.37%) | 0.227 |
≥5cm | 6 (6.67%) | 16 (15.09%) | 4 (14.81%) | |
Unknown | 20 (22.22%) | 14 (13.21%) | 4 (14.81%) | |
Lymph node involvement | ||||
Positive | 22 (24.44%) | 55 (51.89%) | 13 (48.15%) | 0.002 |
Negative | 61 (67.78%) | 46 (43.40%) | 14 (51.85%) | |
Unknown | 7 (7.78%) | 5 (4.72%) | 0 (0.00%) | |
TMN staging | ||||
Stages 0-2 | 63 (70.00%) | 71 (66.98%) | 20 (74.07%) | 0.194 |
Stages >2 | 7 (7.78%) | 19 (17.92%) | 4 (14.81%) | |
Unknown | 20 (22.22%) | 16 (15.09%) | 3 (11.11%) | |
ER/PR status | ||||
Single or double positive | 63 (70.00%) | 68 (64.15%)) | 13 (48.15%) | 0.006 |
Negative | 13 (14.44%) | 26 (24.53%) | 13 (48.15%) | |
Unknown | 14 (15.56%) | 12 (11.32%) | 1 (3.70%) | |
Family history | ||||
Positive | 4 (4.44%) | 3 (2.83%) | (0.00%) | 0.823 |
Negative | 81 (90.00%) | 97 (91.51%) | 25 (92.59%) | |
Unknown | 5 (5.56%) | 6 (5.66%) | 2 (7.41%) | |